Publications by authors named "Kadry Elsaeed"

Claim this Profile
D
Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy.
Raghda N Marzaban, Hesham I AlMekhzangy, Wafaa ElAkel, Tamer M ElBaz, Yehia M ElShazly, Kadry ElSaeed

Arab J Gastroenterol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.
Mohammad El-Sayed, Magdy Elserafy, Maissa El Raziky, Wafaa Elakel, Yasmin Saad, Kadry Elsaeed

Arab J Gastroenterol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
Mohamed El Kassas, Mohamed Alboraie, Heba Omar, Yasmeen Abd El Latif, Mohammed Abd Algaber, Kadry Elsaeed

J Med Virol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study.
Samar K Darweesh, Kadry Elsaeed, Heba Omar, Maissa El Raziky, Wafaa Elakel

Expert Rev Gastroenterol Hepatol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-Life Efficacy of 5 Different Antiviral Regimens for Treatment of Chronic Hepatitis C With Normal Liver Enzymes.
Mohamed El Kassas, Mohamed Alboraie, Kadry Elsaeed, Yasmeen Ahmed, Adel El Tahan

Am J Ther· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens.
Mohamed El Kassas, Mohamed Alboraie, Dalia Omran, Mohamed Salaheldin, Mohamed Naguib Wifi, Kadry Elsaeed

Expert Rev Gastroenterol Hepatol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience.
Aisha Elsharkawy, Maissa El-Raziky, Wafaa El-Akel, Kadry El-Saeed, Rasha Eletreby

J Hepatol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy.
Rasha Eletreby, Mohamed Said, Zeinab Abdellatif, Yasmin Saad, Magdy ElSerafy, Kadry ElSaeed

Hepatol Int· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience.
Mohamed El Kassas, Dalia Omran, Kadry Elsaeed, Mohamed Alboraie, Wafaa Elakel

J Interferon Cytokine Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients.
Saeed Abdelwhab Saeed, Magdy Elsharkawy, Kadry Elsaeed, Osman Fooda

Hemodial Int· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis